{
    "ticker": "RIGL",
    "name": "Rigel Pharmaceuticals, Inc.",
    "description": "Rigel Pharmaceuticals, Inc. is a biotechnology company focused on the discovery and development of novel therapies for the treatment of hematological malignancies and autoimmune diseases. Founded in 2000 and headquartered in South San Francisco, California, Rigel aims to leverage its expertise in drug discovery and development to bring innovative solutions to patients with unmet medical needs. The company\u2019s lead product, TAVALISSE (fostamatinib), is an oral therapy approved for the treatment of chronic immune thrombocytopenia (ITP) in adult patients. Rigel's pipeline also includes multiple candidates targeting various diseases, including autoimmune conditions and cancers. The company's approach combines small molecule drugs with a deep understanding of the mechanisms of disease to create effective therapies. Rigel is committed to advancing science and improving patient outcomes through its research initiatives and collaborations with other organizations in the pharmaceutical and biotech sectors.",
    "industry": [
        "Biotechnology",
        "Pharmaceuticals"
    ],
    "headquarters": "South San Francisco, California, USA",
    "founded": "2000",
    "website": "https://www.rigel.com",
    "ceo": "Raul Rodriguez",
    "social_media": {
        "twitter": "https://twitter.com/RigelPharma",
        "linkedin": "https://www.linkedin.com/company/rigel-pharmaceuticals/"
    },
    "investor_relations": "https://investors.rigel.com",
    "key_executives": [
        {
            "name": "Raul Rodriguez",
            "position": "CEO"
        },
        {
            "name": "James T. McGowan",
            "position": "CFO"
        }
    ],
    "product_categories": [
        {
            "category": "Approved Products",
            "products": [
                "TAVALISSE (fostamatinib)"
            ]
        },
        {
            "category": "Pipeline Candidates",
            "products": [
                "Rigel's Oncology Pipeline",
                "Rigel's Autoimmune Pipeline"
            ]
        }
    ],
    "seo": {
        "meta_title": "Rigel Pharmaceuticals, Inc. | Innovative Therapies for Autoimmune Diseases",
        "meta_description": "Explore Rigel Pharmaceuticals, Inc., a leader in biotechnology focused on developing innovative therapies for hematological malignancies and autoimmune diseases.",
        "keywords": [
            "Rigel Pharmaceuticals",
            "Biotechnology",
            "Pharmaceuticals",
            "TAVALISSE",
            "Chronic Immune Thrombocytopenia",
            "Hematological Malignancies"
        ]
    },
    "faq": [
        {
            "question": "What is Rigel Pharmaceuticals known for?",
            "answer": "Rigel Pharmaceuticals is known for developing therapies for hematological malignancies and autoimmune diseases, including its lead product TAVALISSE."
        },
        {
            "question": "Who is the CEO of Rigel Pharmaceuticals?",
            "answer": "Raul Rodriguez is the CEO of Rigel Pharmaceuticals, Inc."
        },
        {
            "question": "Where is Rigel Pharmaceuticals headquartered?",
            "answer": "Rigel Pharmaceuticals is headquartered in South San Francisco, California, USA."
        },
        {
            "question": "What is TAVALISSE?",
            "answer": "TAVALISSE (fostamatinib) is an oral therapy approved for the treatment of chronic immune thrombocytopenia in adult patients."
        },
        {
            "question": "When was Rigel Pharmaceuticals founded?",
            "answer": "Rigel Pharmaceuticals was founded in 2000."
        }
    ],
    "competitors": [
        "AMGN",
        "BMY",
        "GILD",
        "VRTX"
    ],
    "related_stocks": [
        "ABT",
        "PFE",
        "JNJ",
        "MRK"
    ]
}